Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression
Joint Authors
Park, Young Joo
Ahn, Hwa Young
Kim, Hwan Hee
Hwang, Ji-Yeon
Park, Changhun
Cho, Bo Youn
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-09-27
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Nonalcoholic fatty liver disease or steatohepatitis (NAFLD/NASH) is a fatty liver disease that is closely related to obesity, diabetes, and dyslipidemia.
Pioglitazone, which was developed as an antidiabetic drug, is known to improve NALFD.
Pioglitazone is metabolized by multiple cytochrome P450 (CYP) enzymes, which are regulated by the xenobiotic receptor constitutive androstane receptor (CAR).
In this study, we investigated the effects of pioglitazone on NAFLD by absence of CAR activity under high-fat (HF)-fed conditions.
CAR-/- mice showed significant improvement in NALFD after 12 weeks of pioglitazone treatment compared to wild-type mice.
This improvement in NAFLD persisted in CAR-/- mice regardless of blood pioglitazone concentration.
The expression of lipogenesis genes in the liver, sterol-regulatory element binding protein-1c (SREBP-1c), and stearoyl-CoA desaturase (SCD)-1 was decreased after pioglitazone treatment in HF-fed CAR-/- mice.
In addition, the expression of peroxisome proliferator-activated receptor gamma 2 (PPARγ2) was decreased by pioglitazone in HF-fed CAR-/- mice.
Changes in SREBP-1c and PPAR γ2 remained constant over short-term (6 h) pioglitazone and lipid injection.
Our results showed that NAFLD was improved significantly by pioglitazone in a CAR deletion state.
These results might be valuable because they suggest that interaction with CAR and pioglitazone/PPARγ2 may be important in regulating gene expression associated with NAFLD.
American Psychological Association (APA)
Ahn, Hwa Young& Kim, Hwan Hee& Hwang, Ji-Yeon& Park, Changhun& Cho, Bo Youn& Park, Young Joo. 2018. Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression. PPAR Research،Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1212530
Modern Language Association (MLA)
Ahn, Hwa Young…[et al.]. Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression. PPAR Research No. 2018 (2018), pp.1-10.
https://search.emarefa.net/detail/BIM-1212530
American Medical Association (AMA)
Ahn, Hwa Young& Kim, Hwan Hee& Hwang, Ji-Yeon& Park, Changhun& Cho, Bo Youn& Park, Young Joo. Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression. PPAR Research. 2018. Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1212530
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1212530